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Purpose: To determine the level of clinically acceptable reduction in 
injected fluorine 18 (18F) fluorodeoxyglucose (FDG) dose in 
time-of-flight (TOF)–positron emission tomography(PET)/
magnetic resonance (MR) imaging by using silicon photomul-
tiplier (SiPM) detectors compared with TOF-PET/computed 
tomography (CT) using Lu1.8Y0.2SiO5(Ce), or LYSO, detec-
tors in patients with different body mass indexes (BMIs).
Materials and 
Methods:
Patients were enrolled in this study as part of a larger 
prospective study with a different purpose than evaluated 
in this study (NCT02316431). All patients gave written 
informed consent prior to inclusion into the study. In this 
study, 74 patients with different malignant diseases un-
derwent sequential whole-body TOF-PET/CT and TOF-
PET/MR imaging. PET images with simulated reduction 
of injected 18F-FDG doses were generated by unlisting the 
list-mode data from PET/MR imaging. Two readers rated 
the image quality of whole-body data sets, as well as the 
image quality in each body compartment, and evaluated 
the conspicuity of malignant lesions.
Results: The image quality with 70% or 60% of the injected dose 
of 18F-FDG at PET/MR imaging was comparable to that 
at PET/CT. With 50% of the injected dose, comparable 
image quality was maintained among patients with a BMI 
of less than 25 kg/m2. PET images without TOF recon-
struction showed higher artifact scores and deteriorated 
sharpness than those with TOF reconstruction.
Conclusion: Sixty percent of the usually injected 18F-FDG dose (reduc-
tion of up to 40%) in patients with a BMI of more than 
25 kg/m2 results in clinically adequate PET image quality 
in TOF-PET/MR imaging performed by using SiPM detec-
tors. Additionally, in patients with a BMI of less than 25 
kg/m2, 50% of the injected dose may safely be used.
q RSNA, 2017
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malignant lesions was not assessed, 
and image evaluation was not adapted 
to body mass index (BMI). Thus, the 
goal of our study was to determine the 
level of clinically acceptable reduction 
of injected fluorine 18 (18F)-FDG dose 
in TOF-PET/MR imaging using SiPM 
detectors compared with PET/CT in 
patients with different BMIs.
Materials and Methods
Patients were enrolled in this retro-
spective study as a secondary study 
of a larger prospective study with 
a different purpose than our study 
(NCT02316431). All patients gave writ-
ten informed consent prior to inclusion 
into the study. Thus, the analysis pre-
sented here is based on a retrospective 
review of prospectively acquired data.
There was financial support for this 
study from GE Healthcare on an insti-
tutional level. GE Healthcare employees 
participated in this study as authors. 
Only non–GE Healthcare employees 
had control of inclusion of the data 
and information that might present a 
Despite being one of the most 
widely used imaging modalities in on-
cologic imaging, PET/CT results in con-
siderable medical radiation exposure 
(up to 25 mSv in older systems, and 
approximately 7–10 mSv at modern 
state-of-the-art CT), which is somewhat 
higher than in multidetector contrast 
material–enhanced CT (depending on 
the examination protocol) (3,4). Thus, 
especially for young patients who po-
tentially require repeated follow-up 
studies, the imaging modality with the 
lowest possible absorbed radiation dose 
per examination is desired.
The newly available PET/magnetic 
resonance (MR) imaging systems 
can help reduce the absorbed radia-
tion dose to patients (5–7). In these 
systems, the MR imaging component, 
which does not require the use of ion-
izing radiation, replaces the CT com-
ponent for attenuation correction, ana-
tomic correlation, and diagnostic lesion 
characterization. Additionally, the PET 
component from the latest clinical time- 
of-flight (TOF)-PET/MR imaging 
systems has the potential to reduce 
radiation exposure even further. This 
system uses dedicated silicon pho-
tomultiplier (SiPM) detectors with 
increased sensitivity, which allows 
one to balance reduction of injected 
dose with acquisition time reduction 
(5,8,9). In a pilot study, PET image 
quality with this system was clinically 
acceptable at 50% of the injected 
fluorodeoxyglucose (FDG) dose used 
in conventional PET/CT (5). How-
ever, in that study, only initial results 
were presented, the imaging quality of 
Positron emission tomography (PET)/computed tomography (CT) is widely used for the assessment of 
tumor stage and therapy response (1,2). 
The CT component is used both for atten-
uation correction and for anatomic corre-
lation and characterization of lesions with 
pathologic radiotracer uptake (3).
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Advances in Knowledge
 n Silicon photomultiplier (SiPM) 
detectors, which enable time-of-
flight (TOF)-PET in PET/ 
MR imaging systems, are more 
sensitive than the Lu1.8Y0.2 
SiO5(Ce) (LYSO) crystals in con-
ventional TOF-PET/CT; the 
increased sensitivity of SiPMs 
can be used to lower the injected 
dose of radioactive tracers.
 n PET image quality with simulated 
60% of the standard injected 
dose (reduction of up to 40%) at 
TOF-PET/MR imaging with SiPM 
detectors was found to be com-
parable to that at standard TOF-
PET/CT with LYSO detectors.
 n When 50% of the standard 
injected dose was used (reduc-
tion of up to 50%) in TOF-PET/
MR imaging with SiPM, there 
were significant differences in 
image quality of maximum inten-
sity projections (MIPs), sharp-
ness, and noise among the four 
body mass index (BMI) groups 
(MIP, sharpness in chest and 
noise in pelvist, P , .05; noise in 
chest and upper abdomen, P , 
.01), resulting in acceptable im-
aging quality in the BMI of less 
than 25 kg/m2 group and unac-
ceptable imaging quality in the 
BMI of more than 25 kg/m2 
group.
 n Even when 40% of the standard 
injected dose was used (reduction 
of up to 60%), no lesions were 
missed on PET images with TOF 
reconstruction at PET/MR imaging, 
while with use of 40% of the 
injected dose without TOF recon-
struction, 12 of 138 lesions were 
not safely detected.
Implication for Patient Care
 n In PET scans with SiPM tech-
nology, 60% of the injected dose 
(40% dose reduction) of fluorine 
18 (18F)-fluorodeoxyglucose 
(FDG) in patients with a BMI of 
more than 25 kg/m2 yields ade-
quate PET image quality in TOF 
PET/MR imaging, and in patients 
with a BMI of less than 25 kg/
m2, adequate image quality can 
be obtained with an 18F-FDG 
dose reduction of 50%.
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thickness, 3.3 mm; and pixel size, 1.4 
3  1.4 mm2. Then, whole-body PET data 
were acquired in 3D TOF mode with a 
scan duration of 2 minutes per bed posi-
tion, an axial FOV of 153 mm, and 23% 
overlap of bed positions, resulting in a 
total PET acquisition time of 16–20 mi-
nutes (11).
PET/MR Imaging Examination
PET/CT and PET/MR imaging were 
performed with one radionuclide injec-
tion. For the PET/MR imaging examina-
tion, we used a simultaneous PET/MR 
system, which comprises 3.0-T whole-
body MR imaging and SiPM PET detec-
tors (SIGNA PET/MR; GE Healthcare) 
(12).
Whole-body list-mode PET data 
were acquired in 3D TOF mode with a 
scan duration of 2–4 minutes per bed 
position. The scan time per bed position 
from injection to imaging for PET/MR 
imaging and PET/CT are given in Table 1.
Imaging Examination and Reconstruction
Detailed information on the technical 
acquisition parameters of PET/CT and 
PET/MR imaging is given in Table 2.
PET/CT Examination
The PET/CT acquisition followed a stan-
dard protocol for clinical oncologic im-
aging on a TOF PET/CT scanner (Dis-
covery 690; GE Healthcare, Waukesha, 
Wis) (5,6).
First, a helical CT acquisition was 
performed for attenuation correction 
of PET data. The scan parameters 
were as follows: 120 kVp; 15–80 mA 
with automatic dose modulation; rota-
tion time, 0.5 second; helical thickness, 
3.75 mm; pitch, 39.37 mm per rotation; 
matrix size, 512 3  512 pixels; section 
conflict of interest for those authors 
who are employees of GE Healthcare.
Patients
For inclusion in our study, patients had 
to meet the following criteria: referral 
for initial staging or follow-up of a malig-
nant disease between January 2014 and 
June 2015 in our institution and willing-
ness to undergo the whole-body PET/MR 
imaging examination in addition to the 
clinically indicated PET/CT examination. 
Exclusion criteria were contraindications 
to MR imaging, such as electronically ac-
tive implanted medical devices, metallic 
foreign bodies in sensitive anatomic areas 
(eg, orbita), severe claustrophobia, or a 
body size that did not fit into the PET/MR 
gantry. Patients were classified into four 
groups according to their BMI (, 20, 
. 20 to 25, . 25 to 30, or . 30 kg/m2). 
Detailed patient information and times 
Table 1
Patient Characteristics
Parameter Total BMI , 20 kg/m2 BMI 20–25 kg/m2 BMI 25–30 kg/m2 BMI . 30 kg/m2
No. of patients 74 10 26 25 13
Sex
 Male 45 3 16 18 8
 Female 29 7 10 7 5
Median height (m) 1.72 (1.48–1.90) 1.70 (1.49–1.82) 1.73 (1.49–1.90) 1.70 (1.48–1.90) 1.75 (1.60–1.87)
Median weight (kg) 74 (42–116) 56 (42–63) 69 (54–90) 75 (56–96) 95 (75–116)
Mean patient age (y) 61.4 (29–84) 57.2 (40–74) 62.0 (29–80) 61.0 (31–80) 64.4 (46–84)
 Male patients 61.2 (31–80) 51.0 (47–55) 62.8 (50–80) 60.8 (31–80) 62.9 (46–77)
 Female patients 61.6 (29–84) 59.9 (40–74) 60.8 (29–79) 61.6 (48–72) 65.6 (55–84)
Tumor type
 Head and neck cancer 18 4 8 6
 Breast cancer 2 1 1
 Lung cancer 11 1 6 4
 Esophageal cancer 4 1 2 1
 Gastric cancer 1 1
 Colon cancer 7 1 2 3 1
 Cholangiocarcinoma 2 1 1
 Pancreatic cancer 4 1 3
 Splenic cancer 1 1
 Multiple myeloma 5 1 1 1 2
 Malignant melanoma 4 1 1 2
 Malignant lymphoma 7 2 3 2
 Unknown primary tumor 8 3 1 4
Median injected tracer activity (kBq) 219.5 (177.6–337.5) 186.7 (177.9–212.4) 209.1 (177.6–323.1) 225.0 (180–319.1) 321.1 (221.4–337.5)
Median PET/CT postinjection time (min) 72 (46–104) 72 (46–90) 70 (55–100) 76 (57–104) 73 (60–90)
Median PET/MR postinjection time (min) 77 (37–148) 72 (41–125) 89 (38–144) 60 (42–148) 56 (37–129)
Note.—Data in parentheses are ranges. There was no significant difference in postinjection time between PET/CT and PET/MR imaging in all patients (P = .167).
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by retrospectively unlisting the list-
mode data, as described in the next 
paragraph.
PET Images with Simulated Reduced 
Injected 18F-FDG Doses at PET/MR 
Imaging
To obtain PET images with simulated re-
duced injected 18F-FDG doses, eight sets 
of PET images were reconstructed from 
identical PET emission data from the 
PET/MR acquisition in each patient. We 
retrospectively unlisted the list-mode 
data in the PET images derived from 
PET/MR imaging to obtain a reduced 
amount of emitted counts, equivalent 
to 70%, 60%, 50%, and 40% of counts 
compared with PET images derived from 
PET/CT (hereafter, 70%PET, 60%PET, 
50%PET, and 40%PET). These four sets of 
simulated reduced doses were chosen 
on the basis of the results from a pre-
liminary study (5). For this adjustment, 
the radioactive decay between the ac-
quisition of PET/CT and PET/MR data 
was taken into account. In addition, PET 
image sets were recontructed with TOF 
and without TOF (hereafter, PETTOF and 
PETnon-TOF), which resulted in a total of 
eight reconstructed PET image data sets 
(eg, 70%PETTOF, 
70%PETnon-TOF).
The signal-to-noise ratio of PET 
images was determined according to a 
Poisson counting process (14,15). In this 
situation, signal-to-noise ratio (SNR) 
can be expressed as follows:
=NECR    tSNR 2 ,
where NECR is noise equivalent count 
rate. For the range of simulated reduced 
18F-FDG doses used in clinical practice, 
the noise equivalent count rate curve is 
approximately linear. The image quality 
of simulated dose-reduced PET images 
can therefore be approximated by re-
constructing a fraction of the measured 
counts at full dose.
On the basis of this assumption, we 
created simulated dose-reduced images 
by unlisting the PET data and recon-
structing them based on the percentage 
of used counts (eg, the PET images were 
reconstructed from 2-minute list-mode 
PET data into a 1-minute acquisition, 
which is similar to 50% of the injected 
In PET/MR imaging, OSEM, includ-
ing PSF compensation with three itera-
tions and 16 subsets and a 256 3 256 
image grid (2.34 3 2.34 3 2.78-mm 
voxels), was used for reconstruction of 
the PET images.
The difference in voxel size is due 
to differences in crystal size and FOV. 
Images were filtered in image space by 
using a 4-mm full width at half maxi-
mum in-plane Gaussian filter, followed 
by an axial filter with a three-section 
kernel using relative weights of 1:4:1. 
Scatter correction was applied. For 
PET/MR imging, truncation completion 
was performed by using non–attenua-
tion-corrected PET images. Attenuation 
correction was accomplished by using 
the CT data at PET/CT and the LAVA 
Flex T1-weighted data at PET/MR im-
aging (12). Clinical PET data derived 
from PET/CT were generated by TOF 
calculation from emission data and 
were defined as the standard of refer-
ence for the evaluation and comparison 
with PET images derived from PET/MR 
imaging. PET images with simulated 
reduced injected 18F-FDG doses with 
and without TOF were obtained from 
emission data from PET/MR imaging 
depended on the imaging protocol se-
lected according to the clinical indica-
tion. An axial FOV of 250 mm and 24% 
overlap of bed positions were used, re-
sulting in a total PET acquisition time of 
12–24 minutes. During PET/MR imag-
ing, a 3D liver acquisition with volume 
acquisition (LAVA Flex) T1-weighted 
pulse sequence (repetition time, approx-
imately 4 msec; echo time, 2.23 msec; 
flip angle, 5°; section thickness, 5.2 mm 
with 2.6 mm overlap; 120 sections; pixel 
size, 1.95 3 1.95 mm2, partial Fourier 
70.3%; and acquisition time, 18 seconds 
per bed position) for MR imaging–based 
attenuation correction was performed. 
Additionally, different anatomic MR 
pulse sequences for diagnostic imaging 
were also performed (13).
General PET Reconstruction Parameters
PET images from PET/CT and from 
PET/MR imaging were reconstructed 
by using parameters that were as sim-
ilar as possible. In PET/CT, a fully 3D 
OSEM iterative reconstruction, includ-
ing PSF compensation with three iter-
ations and 18 subsets and a 256 3 256 
image grid (2.73 3 2.73 3 3.27-mm 
voxels), was used.
Table 2
Technical Acquisition Parameters of PET/CT and PET/MR Imaging
Parameter PET/CT PET/MR
Crystal type LYSO SiPM
Crystal size (mm) 4.2 3 6.3 3 25 3.95 3 5.3 3 25
Timing resolution (psec) 544 385
PET transaxial FOV (mm) 810 622
PET axial FOV (mm) 157 250
Overlap between beds (%) 23 24
Scan duration per bed 2 min 2–4-min retrospective unlisting
Total bed acquisition 8–10 6
Attenuation correction CT Dixon MR imaging (4-class)
Reconstruction 3D-OSEM 3D-OSEM
TOF On On and off
PSF On On
Scatter correction On On
Iterations 3 3
Subsets 18 16
Voxel size (mm) 2.73 3 2.73 3 3.27 2.34 3 2.34 3 2.78
Note.—FOV = field of view, LYSO = Lu1.8Y0.2 SiO5(Ce), OSEM = ordered subset expectation maximization, PSF = point spread 
function, 3D = three-dimensional. See also reference 10.
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applicability, we classified simulated PET 
images with a score of 1 as superior or 
comparable to the standard of reference 
and those with a score of 2 as compa-
rable or slightly inferior to the standard 
of reference; both summed scores were 
therefore considered to indicate that the 
images were adequate for clinical imag-
ing. Detailed image quality parameters 
are shown in Figure 1.
The target lesions were extracted by 
the two readers in consensus 3 months 
before the image evaluation. A max-
imum of three FDG-avid lesions per 
body-part compartment (three lesions × 
four compartments = 12 lesions per pa-
tient) were extracted from clinical TOF-
PET/CT data. Of those three lesions, 
one was the smallest lesion and one was 
the biggest malignant lesion per body 
compartment. Overall, 138 lesions were 
evaluated (mean long-axis diameter, 20 
mm 6 18).
The assessment of image quality 
of the PET images with simulated 
reduced 18F-FDG doses derived from 
PET/MR imaging was performed in 
comparison with the standard of ref-
erence (clinical TOF-PET images de-
rived from PET/CT).
Statistical Analysis
To compare the agreement between the 
two readers, we assessed the agreement 
in all scores by calculating the linear-
weighted k. Agreement was defined as 
moderate (k = 0.41–0.60), substantial (k 
= 0.61–0.80), or significant (k . 0.80) 
(17).
Each of the eight simulated PET im-
age data sets was classified on the basis 
of the BMI of the patient into four sub-
groups. To estimate the effect of BMI 
on the result of our scoring, we per-
formed a one-way analysis of variance 
(Kruskal-Wallis test) among four BMI 
groups in a total of 13 categories (MIP 
and three categories [noise, sharpness 
and artifact] × four body parts [head 
and neck, chest, upper abdomen, and 
pelvis] = 12 categories). We consid-
ered clinical and diagnostic quality to 
be insufficient if more than one of the 
13 image quality category scores were 
higher than 2 in more than 10% of each 
patient group.
with the standard of reference. Analysis 
of image quality was performed in three 
steps (Fig 1). First, the overall image 
quality of the whole-body PET with MIP 
(IQMIP) was assessed. Here, a four-point 
scale was used (ranging from a score of 
1 [good] to a score of 4 [not acceptable 
for diagnosis]). Then, images were as-
sessed with regard to artifacts, noise, 
and sharpness in different body com-
partments (head and neck [HN], chest 
[CH], upper abdomen [UA], and pel-
vis [PE] [eg, IQCH_artifact, IQPE_sharpness]) by 
using the same four-point scale. Third, 
the conspicuity of malignant target le-
sions (IQlesion) was noted. For the IQle-
sion, we used a five-point scale where a 
score of 1 meant detection of more than 
75% of the circumference of the lesion 
and a score of 5 meant that no lesion 
was detected. To summarize for clinical 
dose) (14,16). All image reconstructions 
were performed for all patients in all 
BMI groups.
Image Evaluation
Two radiologists (F.d.G.B. and T.S., 
with 8 and 11 years of experience in 
PET reading, respectively) analyzed the 
images in random order. Both readers 
were blinded to the reconstructed set 
and to the simulated injected 18F-FDG 
dose.
For image evaluation, a dedicated re-
view workstation was used (Advantage 
Workstation, version 4.6; GE Health-
care, Waukesha, Wis). The clinical TOF-
PET images from standard PET/CT were 
defined as the standard of reference. 
Readers assessed the eight PET image 
sets (derived from PET/MR) of simu-
lated dose-reduced images compared 
Figure 1
Figure 1: Image quality (IQ ) parameters. Overall, we classified a score of 1 as indicating that 
the image quality of simulated PET images was superior or comparable to the standard of refer-
ence and a score of 2 as indicating that the image quality of simulated PET images was comparable 
or very slightly inferior to the standard of reference; therefore, both scores indicated that the images 
were valid for clinical imaging. MIP = maximum intensity projection.
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quality [IQ]MIP, 0.60; IQartifact, 0.59; IQ-
noise, 0.50; IQsharpness, 0.70; and IQlesion, 
0.73).
Image Quality Analysis: Whole-Body and 
Body Part Compartments
IQMIP and IQartifact, noise, and sharpness of 
70%PET-
TOF and 
60%PETTOF (from PET/MR imag-
ing) were adequate for clinical imaging. 
In these two groups, all image quality 
scores were 2 or lower in 97% of pa-
tients (Table 3). The evaluated 60%PET-
non-TOF, 
50%PETnon-TOF, and 
40%PETnon-TOF im-
ages were rated not adequate in all BMI 
groups. In these groups, more than two 
categories of image quality scores were 
higher than 2 in more than one-third of 
patients (Table 3). The evaluated 40%PET-
TOF was partially not adequate either.
On the basis of these initial analyses, 
we performed further analysis in 50%PET-
TOF and 
70%PETnon-TOF by classifying them 
into the four BMI groups mentioned 
above. For the 50%PETTOF subgroup, 
there were significant differences in sev-
eral image quality evaluations among the 
four BMI groups (IQMIP, IQCH_sharpness, and 
IQPE_noise, P , .05; IQCH_noise and IQUA_noise, 
the PET/CT acquisition was started a 
median of 72 minutes after the injec-
tion (range, 46–104 minutes). PET/MR 
imaging was performed after PET/CT 
in 36 patients and before PET/CT in 
38 patients. The sequence of the PET/
CT and PET/MR imaging examinations 
was determined in a random fashion, 
depending on the clinical workflow and 
the schedule for both systems. The 
PET/MR imaging system is located in 
an adjacent room next to the PET/CT 
room; thus, the time difference be-
tween the start of both acquisitions 
was 34 minutes 6 13 (range, 16–77 
minutes). In five patients, 70%PET could 
not be reconstructed, and in two pa-
tients, 70%PET and 60%PET could not be 
reconstructed. This was due to a lower 
number of emitted counts in the PET/
MR imaging examination (short scan 
duration at PET/MR and/or relatively 
long waiting time between PET/CT and 
PET/MR).
Agreement between Readers
The weighted k between readers 
was moderate to substantial (image 
To clarify the influence of TOF on the 
image quality evaluation, we compared 
all PETTOF with all PETnon-TOF using the 
Wilcoxon signed-rank test with Bonfer-
roni correction, where the P value was 
multiplied by 13.
The generalized estimating equation 
was applied for per-lesion analyses to 
test for clustering of lesions within pa-
tients. The effect of clustering was not 
significant (P . .05 for all) and therefore 
justified the assumption that all lesions 
could be analyzed independently.
P , .05 was considered to indicate 
a significant difference. Weighted k was 
calculated by using R, and the other sta-
tistical analyses were performed with 
SPSS Statistics, version 19.0.0 (IBM, 
Armonk, NY).
Results
Overall, 74 patients were included con-
secutively without further selection (29 
women, 45 men; median age, 63 years; 
range, 29–84 years) (Table 1). The me-
dian injected tracer activity was 219.5 
MBq (range, 177.6–337.5 MBq), and 
Table 3
Image Quality Score of TOF-PET/MR Imaging with SiPM Detectors in All Patients (n = 74)
Parameter
TOF = On TOF = Off
70%PET
TOF
60%PET
TOF
50%PET
TOF
40%PET
TOF
70%PET
non-TOF
60%PET
non-TOF
50%PET
non-TOF
40%PET
non-TOF
Whole-body MIP 1.05 6 0.21 1.08 6 0.25 1.43 6 0.48 1.97 6 0.47 1.05 6 0.21 1.08 6 0.23 1.31 6 0.37 1.68 6 0.40
Body compartments
 Head and neck
  Artifact 1.47 6 0.35 1.47 6 0.36 1.48 6 0.36 1.56 6 0.39 1.76 6 0.50 1.76 6 0.48 1.82 6 0.46 1.85 6 0.46
  Noise 1.03 6 0.15 1.03 6 0.14 1.30 6 0.34 1.84 6 0.31 1.01 6 0.09 1.02 6 0.10 1.26 6 0.29 1.68 6 0.33
  Sharpness 1.01 6 0.06 1.01 6 0.08 1.07 6 0.17 1.18 6 0.27 1.64 6 0.33 1.71 6 0.30 1.81 6 0.27 1.89 6 0.32
 Chest
  Artifact 1.04 6 0.19 1.04 6 0.18 1.05 6 0.19 1.14 6 0.25 1.41 6 0.50 1.45 6 0.49 1.50 6 0.52 1.57 6 0.52
  Noise 1.10 6 0.26 1.16 6 0.30 1.71 6 0.46 2.16 6 0.41 1.13 6 0.34 1.15 6 0.34 1.48 6 0.41 1.87 6 0.44
  Sharpness 1.05 6 0.20 1.08 6 0.26 1.22 6 0.33 1.57 6 0.47 1.91 6 0.30 2.06 6 0.31 2.23 6 0.40 2.51 6 0.41
 Upper abdomen
  Artifact 1.04 6 0.19 1.04 6 0.18 1.05 6 0.19 1.14 6 0.25 1.55 6 0.51 1.58 6 0.51 1.64 6 0.54 1.69 6 0.51
  Noise 1.07 6 0.21 1.12 6 0.27 1.59 6 0.45 2.07 6 0.37 1.07 6 0.22 1.17 6 0.30 1.46 6 0.37 1.89 6 0.42
  Sharpness 1.01 6 0.06 1.03 6 0.11 1.16 6 0.25 1.53 6 0.33 1.97 6 0.24 2.04 6 0.25 2.31 6 0.36 2.62 6 0.37
 Pelvis
  Artifact 1.10 6 0.28 1.09 6 0.27 1.09 6 0.27 1.17 6 0.30 2.08 6 0.38 2.08 6 0.37 2.09 6 0.36 2.09 6 0.36
  Noise 1.10 6 0.22 1.18 6 0.25 1.60 6 0.48 2.09 6 0.36 1.09 6 0.21 1.15 6 0.27 1.41 6 0.33 1.75 6 0.35
  Sharpness 1.04 6 0.13 1.04 6 0.14 1.14 6 0.28 1.48 6 0.33 1.87 6 0.31 2.02 6 0.28 2.24 6 0.32 2.41 6 0.35
Note.—Data are means 6 standard deviations. 
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Lesion Conspicuity
PETTOF was significantly superior to 
PETnon_TOF, even when we compared 
40%PETTOF with 
70%PETnon_TOF (1.53 6 
0.70 vs 2.30 6 1.00, P , .01) (Table 6). 
Although the category IQlesion of 
40%PET-
TOF had somewhat lower scores, no le-
sions were missed. In comparison, in 
PETnon_TOF, several lesions were not de-
finitively detectable on the PET image 
(lesions were actually overlooked dur-
ing the evaluation). In 40%PETnon_TOF, 12 
lesions (8.7%; long-axis diameter, 10.8 
mm 6 3.8; range, 5–21 mm) were not 
reliabily detected by the readers. In 
10 (83.3%) of these 12 patients, PET/
MR imaging was performed after PET/
CT (with the starting time difference in 
scans being 26 minutes 6 6; range, 22–
41 minutes). Images from a representa-
tive examination are shown in Figure 4.
Discussion
In our study, several aspects concern-
ing image quality of PET images with 
simulated reduced 18F-FDG doses from 
while in the group with BMIs of 25–30 
kg/m2 and the group with BMIs of greater 
than 30 kg/m2, these scores were not ad-
equate (Fig 2, Fig E1 [online]).
In 70%PETnon_TOF, there was no sig-
nificant difference among all four BMI 
groups. However, in any of the BMI 
groups, the results of artifact and sharp-
ness evaluation were found to be not 
fully adequate for clinical imaging. Par-
ticularly in IQCH_sharpness, IQUA_sharpness, 
and IQPE_artifact, the average scores were 
approximately  2 and partly above 2 
(Table 4). Images from a representa-
tive examination are shown in Figure 3. 
More detailed results of image quality 
scores are given in Tables E1–E4 (online).
Effect of TOF on Image Quality
The 70%PETnon-TOF images were signif-
icantly inferior to all TOF images with 
regard to artifacts and sharpness. How-
ever, in IQMIP, IQHN_noise, IQCH_noise, and 
IQUA_noise, 
70%PETnon-TOF was superior to 
50%PETTOF and 
40%PETTOF. In IQPE_noise, 
70%PETnon-TOF was superior to 
60%PETTOF, 
50%PETTOF, and 
40%PETTOF (Table 5).
P , .01). In the group with BMIs of less 
than 20 kg/m2 and the group with  BMIs 
of 20–25 kg/m2, IQMIP and IQartifact, noise, and 
sharpness were adequate for clinical imaging, 
Figure 2
Figure 2: Bar chart shows percentage distribution 
of image quality of MIP images among four BMI 
groups in 50%PET
TOF
. Other representative categories 
are given in Figure E1 (online).
Table 4
Image Quality Scores of TOF-PET/MR Imaging with SiPM Detectors in Each BMI Group in 50% of Counts with TOF and 70% Counts 
without TOF (n = 74)
Parameter
50%PET
TOF
70%PET
non-TOF
BMI , 20 kg/m2  
(n = 10)
BMI 20–25 kg/m2  
(n = 26)
BMI 25–30 kg/m2  
(n = 25)
BMI . 30 kg/m2  
(n = 13)
BMI , 20 kg/m2  
(n = 10)
BMI 20–25 kg/m2  
(n = 26)
BMI 25–30 kg/m2  
(n = 25)
BMI . 30 kg/m2  
(n = 13)
Whole-body MIP 1.15 6 0.23 1.33 6 0.34 1.50 6 0.60 1.69 6 0.42 1.00 6 0.00 1.00 6 0.00 1.15 6 0.34 1.00 6 0.00
Body compartments
 Head and neck
  Artifact 1.45 6 0.27 1.50 6 0.34 1.48 6 0.39 1.46 6 0.41 1.72 6 0.53 1.86 6 0.48 1.76 6 0.53 1.62 6 0.40
  Noise 1.20 6 0.33 1.38 6 0.35 1.26 6 0.29 1.31 6 0.37 1.00 6 0.00 1.02 6 0.10 1.02 6 0.10 1.00 6 0.00
  Sharpness 1.05 6 0.15 1.10 6 0.20 1.04 6 0.14 1.08 6 0.18 1.72 6 0.25 1.68 6 0.32 1.54 6 0.36 1.69 6 0.31
 Chest
  Artifact 1.10 6 0.30 1.06 6 0.21 1.04 6 0.14 1.00 6 0.00 1.50 6 0.71 1.39 6 0.56 1.52 6 0.38 1.19 6 0.24
  Noise 1.20 6 0.24 1.62 6 0.37 1.86 6 0.50 2.00 6 0.20 1.00 6 0.00 1.09 6 0.24 1.22 6 0.49 1.12 6 0.21
  Sharpness 1.00 6 0.00 1.17 6 0.24 1.34 6 0.37 1.23 6 0.42 1.94 6 0.28 1.77 6 0.25 2.00 6 0.36 1.96 6 0.13
 Upper abdomen
  Artifact 1.10 6 0.30 1.06 6 0.21 1.04 6 0.14 1.04 6 0.13 1.67 6 0.71 1.52 6 0.57 1.54 6 0.41 1.54 6 0.36
  Noise 1.25 6 0.25 1.58 6 0.41 1.60 6 0.47 1.88 6 0.40 1.06 6 0.16 1.05 6 0.21 1.13 6 0.26 1.04 6 0.13
  Sharpness 1.15 6 0.23 1.15 6 0.27 1.16 6 0.23 1.15 6 0.23 1.94 6 0.16 1.95 6 0.26 1.96 6 0.25 2.04 6 0.24
 Pelvis
  Artifact 1.15 6 0.32 1.12 6 0.32 1.04 6 0.14 1.12 6 0.29 2.22 6 0.67 2.11 6 0.37 2.00 6 0.21 2.08 6 0.33
  Noise 1.30 6 0.33 1.56 6 0.45 1.60 6 0.51 1.92 6 0.38 1.06 6 0.16 1.11 6 0.21 1.11 6 0.25 1.04 6 0.13
  Sharpness 1.00 6 0.00 1.15 6 0.30 1.10 6 0.24 1.27 6 0.32 1.83 6 0.24 1.86 6 0.31 1.87 6 0.26 1.88 6 0.40
Note.—Data are means 6 standard deviations. 
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the image quality, especially in relation 
to artifacts and sharpness. No lesions 
were missed on dose-reduced images 
with TOF.
Our results revealed that simu-
lated 60% of the standard dose for 
all patients, and simulated 50% of the 
Figure 3
was found to be clinically adequate. 
Furthermore, image quality with 50% 
of the simulated standard dose of in-
jected 18F-FDG (reduction of up to 
50%) was comparable in patients with 
low or normal BMIs (BMI , 25 kg/m2). 
Using TOF reconstruction improved 
a TOF-PET/MR imaging system were 
evaluated to find the lowest injectable 
dose of 18F-FDG acceptable for routine 
clinical imaging.
Overall, image quality with simu-
lated 60% of the standard injected dose 
of 18F-FDG (reduction of up to 40%) 
Figure 3: Images in 61-year-old woman with 
unknown primary tumor and a BMI of 31.9 kg/m2. 
PET/CT and PET/MR imaging were performed 73 
and 40 minutes after FDG injection, respectively. 
Upper row: (a) MIP image of PET from TOF-PET/
CT (standard of reference), (b) 70% of the standard 
dose (reduction of up to 30%) with TOF, (c) 40% 
of the standard dose (reduction of up to 60%) with 
TOF, and (d) 70% of the standard dose without TOF. 
(e–h) Corresponding axial images are shown in the 
bottom rows.
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m2 would currently be injected with 3 
MBq of 18F-FDG per kilogram of body 
weight for PET/CT (eg, 75 kg of body 
weight = 225 MBq of injected activity). 
Applying the results of our study, this 
patient would then be injected with 
approximately 112.5 MBq for PET/MR 
imaging, while the same acquisition 
time and adequate clinical image qual-
ity were maintained. With 185 MBq 
equaling an effective absorbed dose of 
around 3.5 mSv, 112.5 MBq would de-
crease the radiation burden to approx-
imately 2.2 mSv for a whole-body PET 
examination (18). Other studies have 
already quantified the dose reduction 
that can be achieved with PET/MR im-
aging compared with PET/CT only by 
omitting the CT component (7). In this 
context, the PET component represents 
the more significant radiation burden 
and thus offers a greater potential for 
reduction of the injected tracer dose. 
Of note, these advantages were tested 
in our study only for body imaging, but 
not for brain imaging. Here, the ad-
vantages are presumably substantially 
smaller because of higher attenuation 
from the head and neck coil, as well 
as from the nonutilization of the whole 
FOV in brain imaging (19,20).
In patients with a BMI of greater 
than 25 kg/m2, a simulated 50% of 
the standard injected dose was not 
considered clinically adequate by the 
readers. This can be explained by the 
fact that, as in PET/CT, the body habi-
tus of larger patients causes more scat-
ter in the images. The TOF component 
partly resolves these issues, and the 
extent of improvement compared with 
thenon-TOF images can be appreciated 
offer the possibility of further dose re-
duction (eg, in younger patients when 
following up specific lesions is the main 
imaging indication).
Several parts of the presented re-
sults can be explained by the tech-
nology used. New detector material 
in conjunction with a larger FOV was 
used, which provides a significantly 
increased sensitivity (11). This effect 
has been proven for other PET/MR 
systems as well (9). To illustrate clini-
cal practicability: In our center, a pa-
tient with a BMI of less than 25 kg/
standard dose in patients with a me-
dium to low BMI, can safely be applied 
in clinical PET/MR imaging. The re-
sults of our study therefore confirm an 
earlier, more preliminary study with a 
smaller number of patients (n = 25) and 
extends the results through the use of 
a more in-depth evaluation of several 
image quality parameters (5). Nota-
bly, lesion detection was not impaired 
even with simulated 40% of the stan-
dard dose. Although image quality was 
considerably decreased, no lesion was 
missed on the TOF images. This might 
Table 5
Comparison of 70%PETnon_TOF with 
70% PETTOF, 
60% PETTOF, 
50% PETTOF, 
40%PETTOF of TOF-PET/
MR Imaging with SiPM Detectors (n = 74)
70%PET
non_TOF
70%PET
TOF
60%PET
TOF
50%PET
TOF
40%PET
TOF
Whole-body MIP Nonsignificant Nonsignificant Superior Superior
Each body part
 Head and neck
  Artifact Inferior Inferior Inferior Inferior
  Noise Nonsignificant Nonsignificant Superior Superior*
  Sharpness Inferior Inferior Inferior Inferior
 Chest
  Artifact Inferior Inferior Inferior Inferior
  Noise Nonsignificant Nonsignificant Superior Superior
  Sharpness Inferior Inferior Inferior Inferior
 Upper abdomen
  Artifact Inferior Inferior Inferior Inferior
  Noise Nonsignificant Nonsignificant Superior Superior
  Sharpness Inferior Inferior Inferior Inferior
 Pelvis
  Artifact Inferior Inferior Inferior Inferior
  Noise Nonsignificant Superior* Superior Superior
  Sharpness Inferior Inferior Inferior Inferior
Note.—All “superior” or “inferior” differences were statistically confirmed with P , .01.
* P , .05.
Table 6
Evaluation of Malignant Lesions at TOF-PET/MR Imaging with SiPM Detectors (n = 138)
Parameter
TOF = On TOF = Off
70%PET
TOF
60%PET
TOF
50%PET
TOF
40%PET
TOF
70%PET
non-TOF
60%PET
non-TOF
50%PET
non-TOF
40%PET
non-TOF
Score* 1.23 6 0.47 1.26 6 0.51 1.35 6 0.59 1.53 6 0.70 2.30 6 1.00 2.39 6 1.00 2.54 6 1.09 2.75 6 1.17
Score . 2.0 5 (3.6) 5 (3.6) 9 (6.5) 17 (12.3) 50 (36.2) 59 (42.8) 64 (46.4) 83 (60.1)
Lesion not detected 0 0 0 0 3 (2.2) 3 (2.2) 7 (5.1) 12 (8.7)
Note.—Unless otherwise specified, data are numbers of lesions, with percentages in parentheses.
* Data are means 6 standard deviations.
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impairs lesion detection more than in 
the lung, for example. Furthermore, 
the conspicuity and detectability of 
the tumor partly also depend on the 
postinjection time. A later scan could 
potentially provide a higher contrast-to-
noise ratio in malignant lesions (22). In 
our study, 10 of 12 lesions missed at 
40%PETnon-TOF were imaged before PET/
CT. Hence, the contrast-to-noise ratio 
in these images might have been lower 
than in the reference image. However, 
the order of the scanning times between 
PET/CT and PET/MR imaging was ran-
domly based on the clinical workflow 
and availability of the scanners. Fur-
thermore, because both systems are lo-
cated in two rooms directly adjacent to 
each other, the difference in acquisition 
start time between both acquisitions 
was not significantly different.
Our study had several limitations. 
First, the resolution of the images was 
inherently different between PET/CT 
and PET/MR imaging. However, there 
is no effective technical method (at 
least no way that would not outstrip 
the focus of our study) to equalize both 
resolutions. In addition, several other 
factors (eg, uptake time, attenuation 
correction method) can affect the PET 
image quality and appearance in patient 
studies (23). Because we mainly made 
qualitative comparisons, those differ-
ences were partly compensated for and 
are largely negligible for the purpose 
of our study, given the setup we used 
(eg, a very low time difference between 
PET/CT and PET/MR imaging). Subsets 
and iterations between TOF-PET/CT 
and TOF-PET/MR imaging were based 
on our routine clinical experience and 
the pertinent literature (11). However, 
these parameters were not additionally 
optimized for non-TOF reconstruction 
at PET/MR imaging. Other publications 
(12,24) have already shown that the 
differences for such comparisons are 
negligible.
In conclusion, a simulated 60% of 
the injected standard dose (reduction of 
up to 40%) of 18F-FDG in patients with 
a BMI greater than 25 kg/m2 still results 
in clinically adequate PET image quality 
at TOF-PET/MR imaging. Additionally, in 
patients with a BMI of less than 25 kg/
50%PETTOF and 
40%PETTOF concerning 
noise. In contrast, IQlesion of 
70%PETnon-
TOF was found to be significantly inferior 
compared with 40%PETTOF; therefore, 
artifacts and/or sharpness—rather than 
noise—seem to be at least equally im-
portant parameters concerning lesion 
conspicuity and detectability.
However, care should be taken re-
garding in which organ or body com-
partment lesions are located. For exam-
ple, images of the liver usually have a 
high degree of noise, and this certainly 
in our results and has already been re-
ported (21). However, this technique 
has its limitations, too. Thus, in very 
large patients, if the same amount of 
injected dose reduction is desired, the 
scan time per bed position might be 
prolonged to achieve good diagnostic 
quality.
There were some discrepancies be-
tween the IQMIP and the image quality 
for several body compartments and the 
IQlesion results. The 
70%PETnon-TOF was 
found to be superior compared with 
Figure 4
Figure 4: Images in 67-year-old man with lung cancer (arrows). (a) Axial PET image from TOF-PET/CT 
(standard of reference), (b) 70% of the standard dose (reduction of up to 30%) with TOF, (c) 40% of the 
standard dose (reduction of up to 60%) with TOF, and (d) 70% of the standard dose without TOF are shown. 
PET/CT and PET/MR were performed 94 and 58 minutes after FDG injection, respectively. On c, the PET 
image with 40% of the dose, the tumor (arrows) is visible, whereas on d, the non-TOF PET image with 70% 
of the standard dose, the tumor is no longer detectable.
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m2, 50% of the injected standard dose 
(reduction of up to 50%) can be safely 
applied as well. Thus, substantially lower 
radiation dose compared with those at 
conventional PET/CT can be achieved in 
PET/MR imaging with SiPM detectors—
not only by omitting the CT component, 
but also by optimizing use of the PET 
component.
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